Leukocyte Adhesion Deficiency Type I – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Leukocyte adhesion deficiency type I (LAD-I), a subtype of LAD defined in the terminology, is characterized by recurring bacterial infections that pose a life-threatening risk. Typically, the initial symptoms manifest during infancy or early childhood. Affected individuals frequently experience recurrent and life-threatening bacterial infections affecting the skin, mouth, and respiratory system. Delayed separation of the umbilical cord is a common occurrence. Skin infections may progress to the formation of extensive ulcers. In later stages of the condition, severe periodontitis often arises, leading to premature tooth loss. Notably, there is a lack of typical signs such as swelling, redness, heat, or pus in the infected areas. LAD-I arises due to mutations in the ITGB2 gene located at 21q22.3. This gene encodes for beta-2-integrin, known as CD18, which plays a vital role in facilitating the firm adhesion of leukocytes to the endothelium. The severity of the disease is closely linked to the extent of deficiency in CD18. Diagnosis hinges on comprehensive blood counts that reveal an elevated number of neutrophils, known as neutrophilic leukocytosis. Flow cytometric analyses show reduced expression of CD18 on leukocytes. Genetic tests for mutations in the ITGB2 gene are performed to confirm the diagnosis. Differential diagnoses include IRAK-4 deficiency, autosomal dominant hyperIgE syndrome, chronic granulomatous disease, other primary immunodeficiencies, and leukemoid reactions. The prognosis depends on the disease's severity. In severe cases of LAD-I, patients face a high risk of succumbing to infections within the first two years of life unless they undergo hematopoietic stem cell transplantation. Conversely, individuals with a moderate form of the condition have a better chance of surviving into adulthood. The survival rate following bone marrow transplantation is approximately 75%.
Thelansis’s “Leukocyte Adhesion Deficiency Type I Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Leukocyte Adhesion Deficiency Type I treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Leukocyte Adhesion Deficiency Type I across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Leukocyte Adhesion Deficiency Type I Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment